Search
MiMedx Group Inc
MDXGAdd to Watchlist
3.930USD
+0.120+3.15%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
585.36MMarket Cap
18.91P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.15%
5 Days
+7.08%
1 Month
+7.08%
6 Months
-43.04%
Year to Date
-41.95%
1 Year
-33.84%
Key Figures
3.830Open
3.975High
5.63MVolume
18.91P/E TTM
29.42P/E Dynamic
--Dividend TTM
3.80%Turnover Ratio
3.810Prev. Close
3.830Low
20.56MTurnover
13.72P/E Static
2.27P/B
0.00%Div Yield TTM
10.60%ROA
7.99052wk High
4.83Volume Ratio
42.42MNet Profit
148.09MShares
0.2078EPS TTM
1.47Beta
13.77%ROE
3.02552wk Low
3.81%Amplitude
70.05%Gross Margin
585.36MMarket Cap
1.53Reward/Risk
2.50%Risk Rate
TradingKey Stock Score of MiMedx Group Inc
Currency: USD Updated: 2026-06-26Key Insights
MiMedx Group Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MiMedx Group Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
MiMedx Group Inc Highlights
StrengthsRisks
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.22% year-on-year.
Fairly Valued
The company’s latest PE is 18.91, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 116.77M shares, increasing 5.02% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 288.09K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.43.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
6.500
Target Price
+70.60%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
MiMedx Group Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MiMedx Group Inc Info
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Ticker SymbolMDXG
CompanyMiMedx Group Inc
CEOCapper (Joseph H)
Websitehttps://mimedx.com/
Related Instruments
+7.01%
+3.85%
+3.63%
+2.35%
+0.12%
+1.36%
+1.56%
+0.78%
+3.26%
+2.60%
+2.32%
+3.81%
+1.16%
+2.75%
-0.01%
0.00%
+2.06%
+1.31%
-0.17%
+1.76%Popular Instruments
51752.200
-272.500 (-0.52%)
28987.500
-467.500 (-1.59%)
7332.000
-34.800 (-0.47%)
15282.000
-469.000 (-2.98%)
69508.000
-1624.000 (-2.28%)
6207.100
-58.700 (-0.94%)
70.148
-1.196 (-1.68%)
283.780
+8.630 (+3.14%)
192.530
-3.210 (-1.64%)
4087.760
+61.610 (+1.53%)
FAQs
What is the current price of MiMedx Group Inc (MDXG)?
The current price of MiMedx Group Inc (MDXG) is 3.93.
What is the symbol of MiMedx Group Inc?
The ticker symbol of MiMedx Group Inc is MDXG.
What is the 52-week high of MiMedx Group Inc?
The 52-week high of MiMedx Group Inc is 7.99.
What is the 52-week low of MiMedx Group Inc?
The 52-week low of MiMedx Group Inc is 3.02.
What is the market capitalization of MiMedx Group Inc?
The market capitalization of MiMedx Group Inc is 582.01M.
Is MiMedx Group Inc (MDXG) currently rated as Buy, Hold, or Sell?
According to analysts, MiMedx Group Inc (MDXG) has an overall rating of Buy, with a price target of 6.50.
What is the Earnings Per Share (EPS TTM) of MiMedx Group Inc (MDXG)?
The Earnings Per Share (EPS TTM) of MiMedx Group Inc (MDXG) is 0.33.
